Investigation Launched by Pomerantz Law Firm for Exelixis Investors Facing Stock Decline

Pomerantz Law Firm Investigates Claims on Behalf of Exelixis Investors

On September 8, 2025, Pomerantz LLP, a leading law firm specializing in corporate and securities class action litigation, announced an investigation concerning potential claims on behalf of investors in Exelixis, Inc. (NASDAQ: EXEL). The firm seeks to understand if there have been any instances of securities fraud or unlawful business practices by Exelixis and some of its executives.

The investigation was prompted after Exelixis released its second-quarter 2025 financial results on July 28, 2025. In this press release, the company met with disappointing news, revealing that its net product revenues for cabozantinib fell short of expectations, reporting approximately 2% below analysts’ consensus estimate of $531.3 million. This financial shortfall, coupled with troubling news regarding their clinical trials, led to a plummet in the company's stock price.

Particularly alarming was Exelixis's announcement that it would not be advancing to phase 3 of its STELLAR-305 study due to emerging competition and an assessment indicating that they would face larger commercial opportunities elsewhere. Following this announcement, Exelixis’s share price took a significant hit, dropping $7.45 per share, or 16.78%, on July 29, closing at $36.94 per share. Such a dramatic fall not only impacts existing investors but raises serious concerns about the company’s operational decisions and communications.

Pomerantz LLP encourages affected investors to step forward and offer their experiences, especially those who have witnessed losses due to the stock's decline. Investors are advised to reach out to Danielle Peyton at Pomerantz, either through phone or email, for further assistance and to discuss potential involvement in a class action lawsuit.

Known for its history and expertise in handling securities fraud cases, Pomerantz has played a pivotal role in advocating for shareholders. For over 85 years, the firm has been at the forefront of securities class action litigation, recovering substantial damages for victims of corporate misconduct.

With offices spanning major cities worldwide, including New York, Chicago, and London, Pomerantz is well-equipped to support investors in their quest for justice against corporate wrongdoings. This ongoing investigation reflects the firm’s commitment to holding companies accountable and ensuring shareholder rights are preserved.

For investors in Exelixis, this could be an opportunity to seek restitution for their financial loss, and the investigation by Pomerantz Law Firm could pave the way for significant legal actions in the future. With securities laws constantly evolving, it is crucial for investors to stay informed and vigilant regarding their investments and understand the legal options available to them.

Conclusion

In summary, the Pomerantz Law Firm is on high alert regarding the potential irregularities with Exelixis, Inc., as the investigation unfolds. Investors facing losses should consider contacting Pomerantz to explore their legal avenues. As the situation develops, it is critical for those affected to keep an eye on forthcoming communications from the firm to ensure their interests are protected.